Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 12/20 | 0.46 |
| ▸ | EHMT1 | Q9H9B1 | 12/20 | 0.46 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 5/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20581729 | 0.92 | EHMT2 (0.50) | EHMT2EHMT1SPIN1METTLR9 | |
| Trifluoroacetic Acid SCHEMBL20581169 | 0.87 | EHMT2 (0.46) | EHMT2EHMT1SPIN1METTLR9 | |
| Trifluoroacetic Acid SCHEMBL20580800 | 0.86 | EHMT2 (0.51) | EHMT2EHMT1SPIN1METPDGFRB | |
| Trifluoroacetic Acid SCHEMBL20580894 | 0.83 | EHMT2 (0.48) | EHMT2EHMT1SPIN1METPDGFRB | |
| SCHEMBL20581115 | 0.83 | EHMT2 (0.52) | EHMT2EHMT1SPIN1METTLR9 | |
| Trifluoroacetic Acid SCHEMBL20580719 | 0.82 | EHMT2 (0.47) | EHMT2EHMT1SPIN1METPDGFRB | |
| Trifluoroacetic Acid SCHEMBL20581388 | 0.81 | EHMT2 (0.45) | EHMT2EHMT1SPIN1METPDGFRB | |
| SCHEMBL20581170 | 0.81 | EHMT2 (0.43) | EHMT2EHMT1SPIN1METTLR9 | |
| SCHEMBL20580801 | 0.80 | EHMT2 (0.48) | EHMT2EHMT1SPIN1METPDGFRB | |
| SCHEMBL20580904 | 0.80 | EHMT2 (0.59) | EHMT2EHMT1SPIN1TLR9TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634962-B1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20210371417-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-11111243-B2 | Azaindole compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| CN-110997671-A | Azaindole compounds as histone methyltransferase inhibitors | 全球血液疗法股份有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20180354947-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111243-B2 | Azaindole compounds as histone methyltransferase inhibitors | EHMT2, EHMT1, EZH2 | EHMT2 1/4885EHMT1 2/4885SPIN1 294/4885 |
| US-20210371417-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT2, EHMT1, EZH2 | EHMT2 1/4885EHMT1 2/4885SPIN1 294/4885 |
| US-20180354947-A1 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT2, EHMT1, EZH2 | EHMT2 1/4885EHMT1 2/4885SPIN1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.